Resveratrol 200mg 30c

Orthoplex

Resveratrol is an antioxidant that may help to support cardiovascular and brain health. See your healthcare practitioner if you think you may need extra cardiovascular or nervous system support.

Gluten Free
Egg Free
Dairy Free
Vegan
Vegetarian
    Product Details

    Pack Size
    30 Capsule

    Adult Dose
    Take 1 capsule daily, or as recommended by your registered healthcare practitioner.

    BIO

    Storage
    Store below 30°C in a cool, dry place, away from direct sunlight.

    Indications

      • Aids, assists or helps in the maintenance of general well-being
      • Possesses antioxidant activity
      • May help to support blood vessels
      • May help to support the peripheral vascular system
      • Supports normal inflammatory mediator activity
      • Supports immune function
      • Supports cardiovascular health

    Ingredients

    Each capsule contains

    Reynoutria japonica root (Std Extract Dry Herb Equiv) 61.2g
    equiv. Resveratrol 200.0mg
    Drug Interactions
    Significance
    Ingredient
    Interaction Descriptions
    Moderate
    HU ZHANG
    (Resveratrol, Reynoutria japonica root (Std Extract Dry Herb Equiv))
    Be cautious with this combination.
    View Interactions:
    Moderate

    CYTOCHROME P450 2C19 (CYP2C19) SUBSTRATES

    Be cautious with this combination.

    Moderate

    CYTOCHROME P450 2C19 (CYP2C19) SUBSTRATES

    Be cautious with this combination.

    Moderate

    CYTOCHROME P450 2C19 (CYP2C19) SUBSTRATES

    Be cautious with this combination.

    Severity: moderate
    Occurrence: possible
    Level of Evidence: D

    Hu zhang contains the constituent resveratrol. Preliminary in vitro evidence shows that resveratrol might inhibit the cytochrome P450 2C19 (CYP2C19) enzyme (70896). Theoretically, hu zhang might increase levels of drugs metabolized by this enzyme due to its resveratrol constituent. However, this interaction has not been reported in humans. Some drugs metabolized by CYP2C19 include amitriptyline (Elavil), carisoprodol (Soma), citalopram (Celexa), diazepam (Valium), lansoprazole (Prevacid), omeprazole (Prilosec), phenytoin (Dilantin), warfarin, and many others.

    References

    70896

    Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectrom. 2003;17(4):307-313.

    Moderate

    CYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES

    Be cautious with this combination.

    Moderate

    CYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES

    Be cautious with this combination.

    Moderate

    CYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES

    Be cautious with this combination.

    Severity: moderate
    Occurrence: possible
    Level of Evidence: D

    Hu zhang contains the constituent resveratrol. Preliminary evidence shows that resveratrol might inhibit the cytochrome P450 3A4 (CYP3A4) enzyme (7864,70896). Theoretically, hu zhang might increase levels of drugs metabolized by this enzyme due to its resveratrol constituent. However, this interaction has not been reported in humans. Some drugs metabolized by CYP3A4 include some calcium channel blockers (diltiazem, nicardipine, verapamil), chemotherapeutic agents (etoposide, paclitaxel, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), glucocorticoids, alfentanil (Alfenta), cisapride (Propulsid), fentanyl (Sublimaze), lidocaine (Xylocaine), losartan (Cozaar), fexofenadine (Allegra), midazolam (Versed), and others.

    References

    7864

    Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91.

    70896

    Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectrom. 2003;17(4):307-313.

    Moderate

    ANTICOAGULANT/ANTIPLATELET DRUGS

    Be cautious with this combination.

    Moderate

    ANTICOAGULANT/ANTIPLATELET DRUGS

    Be cautious with this combination.

    Moderate

    ANTICOAGULANT/ANTIPLATELET DRUGS

    Be cautious with this combination.

    Severity: high
    Occurrence: possible
    Level of Evidence: D

    Hu zhang contains the constituent resveratrol. Resveratrol seems to have antiplatelet effects (2949,2950,2951,2952,2961,56939). Theoretically, taking hu zhang with other antiplatelet or anticoagulant drugs might increase the risk of bruising and bleeding. Some of these drugs include aspirin; clopidogrel (Plavix); nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others); dalteparin (Fragmin); enoxaparin (Lovenox); heparin; warfarin (Coumadin); and others.

    References

    2949

    Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246:163-82.

    2950

    Bertelli AA, Giovannini L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-3.

    2951

    Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19.

    2952

    Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998;24:133-8.

    2961

    Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3.

    56939

    Yang, Y. M., Wang, X. X., Chen, J. Z., Wang, S. J., Hu, H., and Wang, H. Q. Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity. Am J Chin Med 2008;36(3):603-613.

    Moderate

    CYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES

    Be cautious with this combination.

    Moderate

    CYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES

    Be cautious with this combination.

    Moderate

    CYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES

    Be cautious with this combination.

    Severity: moderate
    Occurrence: possible
    Level of Evidence: D

    Hu zhang contains the constituent resveratrol. Preliminary in vitro evidence shows that resveratrol might inhibit the cytochrome P450 1A2 (CYP1A2) enzyme (21733). Theoretically, hu zhang might increase levels of drugs metabolized by this enzyme due to its resveratrol constituent. However, this interaction has not been reported in humans. Some substrates of CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), zileuton (Zyflo), zolmitriptan (Zomig), and others.

    References

    21733

    Chang, T. K., Chen, J., and Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J.Pharmacol.Exp.Ther. 2001;299(3):874-882.

    Moderate

    CYTOCHROME P450 2E1 (CYP2E1) SUBSTRATES

    Be cautious with this combination.

    Moderate

    CYTOCHROME P450 2E1 (CYP2E1) SUBSTRATES

    Be cautious with this combination.

    Moderate

    CYTOCHROME P450 2E1 (CYP2E1) SUBSTRATES

    Be cautious with this combination.

    Severity: moderate
    Occurrence: possible
    Level of Evidence: D

    Hu zhang contains the constituent resveratrol. Preliminary in vitro evidence shows that resveratrol might inhibit the cytochrome P450 2E1 (CYP2E1) enzyme (7864,70896). Theoretically, hu zhang might increase levels of drugs metabolized by this enzyme due to its resveratrol constituent. However, this interaction has not been reported in humans. Some drugs metabolized by CYP2E1 include acetaminophen, chlorzoxazone (Parafon Forte), ethanol, theophylline, and anesthetics such as enflurane (Ethrane), halothane (Fluothane), isoflurane (Forane), methoxyflurane (Penthrane).

    References

    7864

    Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91.

    70896

    Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectrom. 2003;17(4):307-313.

    Moderate

    ESTROGENS

    Be cautious with this combination.

    Moderate

    ESTROGENS

    Be cautious with this combination.

    Moderate

    ESTROGENS

    Be cautious with this combination.

    Severity: moderate
    Occurrence: possible
    Level of Evidence: D

    Hu zhang appears to have estrogenic activity (13124,16061). Theoretically, hu zhang might competitively inhibit the effects of estrogen replacement therapy.

    References

    16061

    Zhang CZ, Wang SX, Zhang Y, et al. In vitro estrogenic activities of Chinese medicinal plants traditionally used for the management of menopausal symptoms. J Ethnopharmacol 2005;98:295-300.

    13124

    Matsuda H, Shimoda H, Morikawa T, Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorg Med Chem Lett 2001;11:1839-42.

    Minor

    CARBAMAZEPINE (Tegretol)

    Be watchful with this combination.

    Minor

    CARBAMAZEPINE (Tegretol)

    Be watchful with this combination.

    Minor

    CARBAMAZEPINE (Tegretol)

    Be watchful with this combination.

    Severity: mild
    Occurrence: possible
    Level of Evidence: D

    Hu zhang might increase levels of carbamazepine. In animals, blood and tissue levels of carbamazepine were increased when given in combination with hu zhang. It is likely that increased levels of carbamazepine are due to cytochrome P450 3A4 (CYP3A4) inhibition (101418). This interaction has not been reported in humans. However, it is possible that the combination of hu zhang and carbamazepine might increase side effects of carbamazepine.

    References

    101418

    Chi YC, Lin SP, Hou YC. A new herb-drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in rats. Toxicol Appl Pharmacol 2012;263(3):315-22.


    Full Reference List

    16061
    Zhang CZ, Wang SX, Zhang Y, et al. In vitro estrogenic activities of Chinese medicinal plants traditionally used for the management of menopausal symptoms. J Ethnopharmacol 2005;98:295-300.
    13124
    Matsuda H, Shimoda H, Morikawa T, Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorg Med Chem Lett 2001;11:1839-42.
    7864
    Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91.
    70896
    Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectrom. 2003;17(4):307-313.
    21733
    Chang, T. K., Chen, J., and Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J.Pharmacol.Exp.Ther. 2001;299(3):874-882.
    2949
    Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246:163-82.
    2950
    Bertelli AA, Giovannini L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-3.
    2951
    Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19.
    2952
    Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998;24:133-8.
    2961
    Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3.
    56939
    Yang, Y. M., Wang, X. X., Chen, J. Z., Wang, S. J., Hu, H., and Wang, H. Q. Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity. Am J Chin Med 2008;36(3):603-613.
    101418
    Chi YC, Lin SP, Hou YC. A new herb-drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in rats. Toxicol Appl Pharmacol 2012;263(3):315-22.

    Rating System Description

    Level of Significance: Stop‑Light Rating System Occurrence/Severity
    Major

    Do not use combination; contraindicated; strongly discourage patients from using this combination; a serious adverse outcome could occur.

    Moderate

    Use cautiously or avoid combination; warn patients that a significant interaticon or adverse outcome could occur.

    Minor

    Be aware that there is a chance of an interaction; advise patients to watch for warning signs of a potential interaction.

    Likelihood of Occurrence

    Likely: Well‑controlled human studies have demonstrated existence of this interaction.

    Probable: Interaction has not been documented in well‑controlled studies, however interaction has been demonstrated in human studies or in controlled animal studies plus multiple case reports.

    Possible: Interaction has been documented in animal or in vitro research, or interaction has been documented in humans but is limited to case reports or conflicting clinical research.

    Unlikely: Interaction has been demonstrated in animal or in vitro research but has been shown not to occur in humans.

    Severity

    High: Life threatening or requires medical intervention to prevent a serious adverse event.

    Moderate: Worsened clinical status and/or requires medication adjustment.

    Mild: May cause minor clinical side effects. Unlikely to require medication adjustment.

    Insignificant: Drug or supplement levels may be affected but will not cause clinical effects.

    Level of Evidence

    A: High-quality randomized controlled trial(RCT).

    A: High-quality meta-analysis (quantitative systematic review)

    B: Nonrandomized clinical trial

    B: Nonquantitative systematic review

    B: Lower quality RCT

    B: Clinical cohort study

    B: Case-control study

    B: Historical control

    B: Epidemoilogic study

    C: Consensus

    C: Expert opinion

    D: Acecdotal evidence

    D: In vitro or animal study

    D: Theoretical based on pharmacology


    © 2019 TRC is a registered trademark of Therapeutic Research Center.
    TRC and all associated names and service marks including TRC are restricted and reserved for Therapeutic Research Center use.
    Natural Medicines™ and associated Natural Medicines product marks are trademarks of Therapeutic Research Center.

    Disclaimer: This information on interactions is licensed from the TRC Natural Medicines Database. Neither Bio Concepts nor TRC are providing medical, clinical or other advice and nothing should be interpreted as constituting such advice. Currently this does not check for drug-drug or supplementsupplement interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgement is necessary.